Abstract
Background Reliable surveillance systems are essential to assess the national response to eliminating hepatitis C virus (HCV), in the context of the global strategy towards eliminating viral hepatitis.
Aim We aimed to assess the completeness of the two national registries of acute HCV infection in people with HIV, and estimated the number of acute HCV infections among adults with HIV in the Netherlands.
Methods For 2003-2016, cases of HCV infection and reinfection among adults with a positive or unknown HIV-serostatus were identified in two national registries: the ATHENA cohort, and the National Registry for Notifiable Diseases. For 2013-2016, cases were linked, and two-way capture-recapture analysis was carried out.
Results During 2013-2016, there were an estimated 282 (95%CI: 264-301) acute HCV infections among adults with HIV. The addition of cases with an unknown HIV-serostatus increased the matches (from N=104 to N=129), and a subsequently increased the estimated total: 330 (95%CI: 309-351). Underreporting was estimated at 14-20%.
Conclusion In 2013-2016, up to 330 cases of acute HCV infection were estimated to have occurred among adults with HIV. National surveillance of acute HCV can be improved by increased notification of infections. Surveillance data should ideally include both acute and chronic HCV infections, and be able to distinguish between acute and chronic infections, and initial and reinfections.
Classifications The Netherlands; sexually transmitted infections; hepatitis C; HIV infection; Surveillance; epidemiology
Competing Interest Statement
TSB, EOdC, MP, JTMvdM, BvB, and CS have nothing to disclose. JA reports other from Gilead, other from Janssen, other from BMS, other from Abbvie, other from MSD, other from ViiV, grants from MSD, grants from ViiV, grants from BMS, grants from Abbvie, outside the submitted work. MvdV reports grants and personal fees from Abbvie, personal fees from BMS, grants and personal fees from Gilead, grants and personal fees from Johnson & Johnson, grants, personal fees and non-financial support from MSD, personal fees from ViiV, outside the submitted work. PR reports grants from Gilead Sciences, grants from ViiV Healthcare, grants from Janssen Pharmaceutica, grants from Merck&Co, grants from Bristol Myers Squibb, other from Gilead Sciences, other from ViiV Healthcare, other from Merck&Co, other from Teva Pharmaceutical Industries, other from Janssen Pharmaceutica, outside the submitted work.
Funding Statement
The National Register for Notifiable Diseases is maintained by the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment, which is supported by the Dutch Ministry of Health, Welfare and Sport. The ATHENA cohort is managed by Stichting HIV Monitoring and supported by a grant from the Dutch Ministry of Health, Welfare and Sport through the Centre for Infectious Disease Control of the National Institute for Public Health and the Environment.
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
The data used in this study are confidential and would not be shared. The ATHENA cohort data are available on request at SHM; for more information: https://www.hiv-monitoring.nl/english/research/research-projects/research-proposal/.